A prospective observational study on efficacy of serial low dose infusion of rituximab (500 mg) on patients of pemphigus
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20203527Keywords:
Rituximab, Complete remission, Pemphigus, Mean duration, Low doseAbstract
Background: Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody being increasingly used in management of pemphigus. Various studies show a lack of any uniform treatment protocol. The objective of the study was to assess the effectiveness of RTX in patients of pemphigus receiving serial low doses of RTX (500 mg; maximum of 4 doses; 2 weeks apart).
Methods: It was a prospective observational review of 40 pemphigus patients to assess the proportion of patients achieving complete remission after serially receiving low dose RTX, time and number of doses required to achieve complete remission (CR), proportion of patients who responded partially or didn’t respond or relapsed after achieving CR. Additionally, the study was done to find whether a correlation existed between age, gender, and site of lesion and RTX administration.
Results: 40 pemphigus patients followed up for a mean duration (MD) of 174.15±95.67 days received 4 doses of RTX (500 mg) irrespective of the disease activity 0.30 (75%) attained CR on therapy with ≥3 doses of RTX 500 mg (MD= 76.39±34.45 days) and azathioprine 100 mg/day. No patients relapsed after 4 doses while 3 (7.5%) patients didn’t respond. Oral lesions and pemphigus vulgaris took more time for achieving CR.
Conclusion: While we reinforce the idea of using more than 3 doses of RTX 500 mg in a view to achieve prolonged remission we promote considering usage of a more cost-effective drug like azathioprine for maintaining remission especially in a poor remote tertiary center in India with limited resources. Immunological assays were not performed limiting the study.
Metrics
References
Kanwar AJ, Ajith AC, Narang T. Pemphigus in North India. J Cutan Med Surg. 2006;10:21-5.
Sehgal VN. Pemphigus in India. A note. Indian J Dermatol. 1972;18:5-7.
Lever WF, Schaumburg‑Lever G. Immuno-suppressant’s and prednisone in pemphigus vulgaris: Therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113:1236‑41.
Pasricha JS, Gupta R. Pulse therapy with dexamethasone‑cyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984;50:199‑203.
Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132:203-12.
Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66:142‑4.
Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;271‑7.
Joly P, Maho‑Vaillant M, Prost‑Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First‑line rituximab combined with short‑term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel‑group, open‑label randomised trial. Lancet. 2017;389:2031‑40.
Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: A systematic review and meta‑analysis of different regimens. Acta Derm Venereol. 2015;95:928‑32.
Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14:323‑31.
Heelan K, Al‑Mohammedi F, Smith MJ, Knowles S, Lansang P, Walsh S, et al. Durable remission of pemphigus with a fixed‑dose rituximab protocol. JAMA Dermatol. 2014;150:703‑8.
Amber KT, M. Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J European Academy Dermatol Venereol. 2014;29(4):777-82.
Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;27:1‑7.
Dedee F. Murrell et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-46.
Weiner GJ. Rituximab: Mechanism of action. Semin Hematol 2010;47:115‑23.
Gupta V, Khaitan BK. Therapeutic potential of biosimilars in dermatology. Indian J Dermatol Venereol Leprol. 2015;81:451‑6.
Sharma V, Bhari N, Gupta S, Sahni K, Khanna N, Ramam M, et al. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study. Indian J Dermatol Venereol Leprol. 2016;82:389‑94.
Londhe P, Khopkar U, Kalyanpad Y. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus. Indian J Dermatol Venereol Leprol. 2014;80:300.
Khopkar US, Chadha AA, Nitya MS, Lahoria V. Follow‑up data of rituximab as adjuvant therapy in pemphigus. Indian J Dermatol. 2017;62:671‑3.
Ahmed AR, Shetty S. The emerging role of rituximab in autoimmune blistering diseases. Am J Clin Dermatol. 2015;16:167-77.
Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166:405-12.
Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341-9.
Gupta J, Raval RC, Shah AN, Solanki RB, Patel DD, Shah KB, Badheka AD, Shah KB, Aggarwal NK, Ravishankar V. Indian J Dermatol Venereol Leprol. 2017;83(3):317-25.
Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O. Therapy with rituximab for autoimmune pemphigus: Results from a single centre observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617-22.
Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928-32.
Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165(3):646-51.
Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111-19.
Gopaluni S, Smith RM, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017;18(1):112.
Vinay K, Kanwar AJ, Mittal A, Dogra S, Minz RW, Hashimoto T. Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris. JAMA Dermatol. 2015;151:878‑82.
Joly P, Maho‑Vaillant M, Prost‑Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First‑line rituximab combined with short‑term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel‑group, open‑label randomised trial. Lancet. 2017;389:2031‑40.
